why choose us

First received: August 28, 2023

Clinical Trial: A Study of CRD3874-SI in People With Sarcoma or Merkel Cell Cancer

Study Status: Completed

Recruit Status: RECRUITING

Condition: Sarcoma

Study Type: INTERVENTIONAL


Official Title: A Phase I Trial of CRD3874-SI, a STING Agonist, in Patients With Advanced/Metastatic Sarcoma and Merkel Cell Carcinoma

Brief Summary: This study will test the safety of a study drug called CRD3874-SI.The researchers will test different doses of CRD3874-SI to find the highest dose that causes few or mild side effects in participants.After the researchers find the highest safe dose of CRD3874-SI, they will test that dose in new groups of participants to help them learn more about the side effects of the study drug and find out whether CRD3874-SI is an effective treatment for Sarcoma and Merkel Cell Cancer.

Read more